Image for representational purpose only. (Photo | AP) 
India

SII applies for full market authorisation of Covishield as supplies of vaccine exceeded 125 crore doses

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government

PTI

NEW DELHI: Serum Institute of India (SII) CEO Adar Poonawala on Friday said it has applied to Indian authorities for full market authorisation of Covishield, stating supplies of the COVID-19 vaccine have exceeded 125 crore doses.

SII had partnered with the developer of Covishield, AstraZeneca, for the supply of the vaccine to the Indian government, which had in January this year granted emergency use authorisation in the country.

"Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission," Poonawala said in a tweet tagging the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare.

At least 26 killed as minibus collides head-on with container truck near Kaziranga National Park in Assam

Visas a 'sovereign' matter, says MEA as Tharoor alleges 115 Bharat Summit speakers barred

What IAF's Gajraj landing at Nyoma, the border with China, means

Microsoft restores parts of India, APAC infrastructure after global service disruption

'Proof against Modi on my phone': Rahul alleges PM tapping device, renews debate call